Influenza vaccine uptake among at-risk adults (aged 16–64 years) in the UK

A retrospective database analysis

Bibliographic Data

ID15364508
AuthorsSimon Oakley (0000-0003-1302-8697, Sanofi (United Kingdom), corresponding author), Julien Bouchet (Sanofi (France)), Paul Costello (Sanofi (United Kingdom)), James Parker (0000-0003-1184-5036, Sanofi (United Kingdom))
Year2021
Volume21
Issue1
Pages1734-1734
Publication date2021-09-24
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueBMC Public Health (JOURNAL)
Journal identifiersISSN: 1471-2458 • E-ISSN: 1471-2458
PublisherBioMed Central (PUBLISHER • GB)
DOI10.1186/s12889-021-11736-2
PMID34560879
OpenAlexW3200449250
LanguageEN
Citations received2
References cited34

Uptake of the influenza vaccine by adults aged 16-64 years in a clinical at-risk group was substantially below the national ambitions. As a result, many individuals in the UK remain at high risk of developing severe influenza or complications. Given that people who are vulnerable to COVID-19 are also at increased risk of complications from influenza, during the 2020-2021 season, there is a heightened need for healthcare professionals across the UK to address suboptimal vaccine uptake, particularly in at-risk patients. Healthcare professionals and policymakers should consider measures targeted at increasing access to and awareness of the clinical benefits of the influenza vaccine

Biostatistics · Environmental health · Influenza vaccine · Public health · Retrospective cohort study · Vaccination · Young adult · Demography · Diabetes and associated disorders · Influenza Virus Research Studies · Medicine · Vaccine Coverage and Hesitancy · Epidemiology · Gerontology · Immunology · Internal Medicine · Pediatrics

Tools

Open DOIOpen Access